Jaguar Health, Inc.: Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher
(2) This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time. Webcast registration and participation link appears below SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has ent...
Lisa Conte Peter Hodge Centers For Disease Jaguar Health Inc National Institute Of Allergy National Institutes Of Health
Source: finanznachrichten.de